Stockscreener 앱 받기
4.65
9.93%
0.42
Inmed Pharmaceuticals Inc 주식(INM)의 최신 뉴스
InMed Pharmaceuticals (FRA:MWG) EBITDA : €-6.11 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Earnings per Share (Diluted) : €-59.16 (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Asset Turnover : 0.11 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cost of Goods Sold : €3.11 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Intrinsic Value: DCF (Earni - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Free Cash Flow : €-6.08 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) COGS-to-Revenue : 0.61 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Earnings Yield (Joel Greenb - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Debt-to-Revenue : 0.21 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Price-to-Owner-Earnings : (As of Nov. 21, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash-to-Debt : 5.28 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted PB Rati - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash Flow for Dividends : €0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted FCF per Share : €-485.97 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted Book pe - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Forward Dividend Yield % : 0.00% (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted PS Rati - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Inventories, Finished Goods : €0.84 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year Book Growth Rate : -64.40% (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Other Current Liabilities : €0.21 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EPS (Basic) : €-59.16 (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Other Long-Term Liabilities : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash From Discontinued Inve - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Other Long Term Assets : €0.09 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash Ratio : 3.89 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash Flow from Investing : €-0.01 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EBIT : €-6.66 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Peter Lynch Fair Value : €-1,493.15 (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash From Other Investing A - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Long-Term Capital Lease Obl - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Total Stockholders Equity : €7.56 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EV-to-EBITDA : 0.22 (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted Revenue per Share : €68.91 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Purchase Of Investment : €-0.04 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Change In Receivables : €-0.11 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year EPS without NRI Grow - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EPS without NRI : €-59.73 (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Other Stockholders Equity : €-0.00 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Change In Inventory : €-0.28 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Net Issuance of Preferred S - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EPS (Diluted) : €-59.16 (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Short-Term Capital Lease Ob - GuruFocus.com
InMed’s Study Highlights Cannabinol’s Potential in Skincare - TipRanks
InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System - Newsfile
InMed Pharmaceuticals Reports Improved Quarterly Earnings - TipRanks
InMed Pharmaceuticals (STU:MWG) Debt-to-EBITDA : -0.13 (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year Revenue Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Growth Rank : 0 (As of Nov. 17, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Issuance of Stock : €4.27 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Change In Working Capital : €-0.33 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Net Issuance of Debt : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Repurchase of Stock : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Inventory-to-Revenue : 0.95 (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) PensionAndRetirementBenefit : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash Flow from Financing : €4.27 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Deferred Tax : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year EBITDA Growth Rate : 70.10% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Retained Earnings : €-101.33 Mil (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) ROE % Adjusted to Book Value : -14.96% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 50-Day SMA : €4.49 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) FCF Yield % : -226.50 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) PE Ratio without NRI : At Loss (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Volatility : 115.20% (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Capex-to-Operating-Cash-Flo - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Momentum Rank : 3 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year FCF Growth Rate : 71.00% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EBITDA per Share : €-24.28 (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Gross Profit : €1.02 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Revenue per Share : €12.67 (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 5-Day RSI : 43.89 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Enterprise Value : €-2.41 Mil (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Forward Rate of Return (Yac - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Peter Lynch Fair Value : €-607.53 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Effective Interest Rate on Debt % : 0.00% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Total Assets : €10.98 Mil (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 5-Year EBITDA Growth Rate : 55.00% (As of Jun. 2024) - GuruFocus.com
0.93%
3.55%
자본화:
|
볼륨(24시간):